The abstract is read at the publisher; the summary is JClub's.
Therapeutic cancer vaccines can induce tumour-specific immune responses, but durable tumour control remains limited, with clinical benefit most evident in earlier disease settings and when combined with broader immunotherapy strategies.
- Why it matters: The field faces a gap between immunogenicity and sustained tumour control, likely driven by bottlenecks spanning antigen selection, presentation, T cell priming, tumour infiltration, and immune suppression resistance.
- What they did: The Review synthesizes advances in neoantigen discovery, vaccine platforms, immune profiling, and computational biology, focusing on clinical trial evidence for neoantigen-directed vaccines and how biomarkers and immune strategies could be used.
- The result: Evidence suggests therapeutic vaccination can improve clinical outcomes, especially when used earlier and integrated with other immunotherapies, guiding next-generation vaccine design and biomarker-driven treatment approaches.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.